umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma
Show others and affiliations
2018 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 28, p. 568-568Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Clinical medicine hopes for the development of reliable tumor markers, on the basis of which there can be chosen the optimal treatment program for uterine sarcoma patients, and also make a prognosis. The hyperexpression of PD-L1 in different tumors such as melanoma, kidney cancer, non-small cell lung cancer correlates with unfavorable prognosis of the disease. The role of PD-L1 expression, as a tumor marker in sarcoma, remains unclear.

Objective: The investigation of PD-L1 expression as a prognostic tumor marker for uterine sarcoma.

Methods: There have been selected 30 uterine sarcoma patients stage I-II (T1-2NxM0), for immunohistochemistry analyze of PD-L1 expression. Depending on the morphological tumor types all the patients were distributed: leiomyosarcoma (LMS) - 20.0%, endometrial stromal sarcoma (ESS) - 46.7%, undifferentiated sarcoma (HC) - 33.3%.

Results: Our results showed that 73.3 % of patients with uterine sarcoma showed a low expression level of PD-L1. The moderate level and overexpression of PD-L1 were observed in the undifferentiated and endometrial stromal sarcoma (fig.1) – in 13.3 and 6.7 %, respectively. At further follow-up of patients with PD-L1 expression, the relapse of the disease was detected in 50.0 % of cases.

Conclusion: The PD-L1 expression in tumor tissue, regardless of its level, is considered to be an unfavorable prognostic factor for the uterine sarcoma patients. In case of moderate expression level of PD-L1, so as at its overexpression, the tumor progression was detected in 83.3% of uterine sarcoma patients.

Place, publisher, year, edition, pages
BMJ Publishing Group Ltd, 2018. Vol. 28, p. 568-568
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:umu:diva-161558DOI: 10.1097/01.IGC.0000547510.84464.baISI: 000471152401151OAI: oai:DiVA.org:umu-161558DiVA, id: diva2:1336816
Note

Suppl. 2

Meeting abstract: IGCS8-1478

Available from: 2019-07-10 Created: 2019-07-10 Last updated: 2019-07-10Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text
By organisation
Umeå University
In the same journal
International Journal of Gynecological Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf